Frontiers in Neurology (Oct 2021)

The Genotype and Phenotype Features in a Large Chinese MFN2 Mutation Cohort

  • Yan Ma,
  • Yan Ma,
  • Yan Ma,
  • Aping Sun,
  • Aping Sun,
  • Aping Sun,
  • Yingshuang Zhang,
  • Yingshuang Zhang,
  • Yingshuang Zhang,
  • Dongsheng Fan,
  • Dongsheng Fan,
  • Dongsheng Fan,
  • Xiaoxuan Liu,
  • Xiaoxuan Liu,
  • Xiaoxuan Liu

DOI
https://doi.org/10.3389/fneur.2021.757518
Journal volume & issue
Vol. 12

Abstract

Read online

Introduction: Charcot–Marie–Tooth disease type 2A (CMT2A) is a group of clinically and genetically heterogeneous disorders, which is mostly caused by mutations of the mitofusin2 (MFN2) gene. As the genotype–phenotype characteristics of CMT2A were still incompletely understood, we further explored the spectrum of CMT2A variants in China and demonstrated their phenotypic diversities.Methods: A total of 402 index patients/families with CMT throughout Mainland China were enrolled in this study. Among them, we analyzed 20 unrelated index cases with CMT2A by Sanger sequencing, next-generation sequencing, or whole-exome sequencing. Detailed clinical and genetic features of CMT2A patients were collected and analyzed. Of note, de novo mutations were not rare in MFN2 gene; we compared the clinical features of patients from the de novo group with those from the non-de novo group.Results: We identified 20 MFN2 variants, occupying 5.0% of CMT. Most patients presented with early onset and moderate phenotype with abnormal gait and foot drop as the main complaints at onset. Pyramidal signs accounts for 31.6% (6/19) in all patients, which is not uncommon. Four novel variants (p.Tyr752*, c.475-2A>G, p.Val99Met, and p.Arg275_Gln276insArg) were identified in the cohort. Besides, de novo variants occupied 35.0% (7/20) in our study with a much earlier age at onset compared with those in the non-de novo group (p = 0.021).Conclusion: Chinese CMT2A is a predominant typical pure CMT2A, with early onset and mild to moderate phenotype. Given the high frequency of de novo MFN2 mutations, genetic study should be considered for patients with early onset and severe idiopathic axonal neuropathy.

Keywords